Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy

Rani, Aradhana; Stebbing, Justin; Giamas, Georgios; Murphy, John J.

doi:10.3389/fendo.2019.00245

Cited by 171 publications

(156 citation statements)

References 430 publications

(489 reference statements)

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…For example, acquired endocrine-resistant disease may represent up to one-quarter of all breast cancers [68][69][70]. Moreover, the agonist effect of tamoxifen may induce a risk of endometrial cancer after long-term use in postmenopausal women [71]. Generally, AIs and fulvestrant are used to follow or replace when patients are resistant to tamoxifen [71,72].…”

Section: Endocrine Resistancementioning

confidence: 99%

Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1

Song

Sinha

et al. 2019

Oncogene

View full text Add to dashboard Cite

show abstract

Section: Endocrine Resistancementioning

confidence: 99%

Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1

Song

Sinha

et al. 2019

Oncogene

View full text Add to dashboard Cite

show abstract

“…Chemotherapeutic interventions for breast cancer depend primarily on the estrogen and progesterone hormonal status of the tumors. Whether localized or disseminated, the treatment of choice is based on endocrine therapies, including selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor down-regulators (SERDs) [7]. A third receptor, HER2/neu (human epidermal growth factor receptor 2), is overexpressed in up to 20% of breast cancers and it is targeted with receptor blockers including trastuzumab, pertuzumab, neratinib, and lapatinib [8].…”

Section: Introduction-history Of Breast Cancer Current Management Amentioning

confidence: 99%

Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae

Benesch

Tang

Brindley

2020

Cancers

View full text Add to dashboard Cite

After a decade of intense preclinical investigations, the first in-class autotaxin inhibitor, GLPG1690, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. In the intervening time, a deeper understanding of the role of the autotaxin–lysophosphatidate (LPA)–lipid phosphate phosphatase axis in breast cancer progression and treatment resistance has emerged. Concordantly, appreciation of the tumor microenvironment and chronic inflammation in cancer biology has matured. The role of LPA as a central mediator behind these concepts has been exemplified within the breast cancer field. In this review, we will summarize current challenges in breast cancer therapy and delineate how blocking LPA signaling could provide novel adjuvant therapeutic options for overcoming therapy resistance and adverse side effects, including radiation-induced fibrosis. The advent of autotaxin inhibitors in clinical practice could herald their applications as adjuvant therapies to improve the therapeutic indexes of existing treatments for breast and other cancers.

show abstract

“…It isn’t clear what control region in the HPV16 LCR is responsible for transcriptional repression following estrogen treatment. However, it has been shown that the ERα can interact with AP1 via c-Jun and there are known AP1 binding sites in the HPV16 LCR that may mediate the response of this region to estrogen(66–72). This will be investigated in future studies.…”

Section: Discussionmentioning

confidence: 99%

Estrogen attenuates the growth of human papillomavirus positive epithelial cells

Bristol

James

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

12Human papillomaviruses (HPVs) are small, double-stranded DNA viruses that are 13 significant risk factors in the development of cancer, and HPV accounts for 14 approximately 5% of all worldwide cancers. Recent studies using data from The Cancer 15 Genome Atlas (TCGA) have demonstrated that elevated levels of estrogen receptor 16 alpha (ERα) are associated with improved survival in oropharyngeal cancers, and these 17 elevated receptor levels were linked with human papillomavirus positive cancers 18 (HPV+cancers). There has been a dramatic increase in HPV-related head and neck 19 squamous cell carcinomas (HPV+HNSCCs) over the last two decades and therapeutic 20 options for this ongoing health crisis are a priority; currently there are no anti-viral 21 therapeutics available for combating HPV+cancers. During our own TGCA studies on 22 head and neck cancer we had also discovered the overexpression of ERα in 23 HPV+cancers. Here we demonstrate that 17β-estradiol (estrogen) attenuates the 24 growth/cell viability of HPV+cancers in vitro, but not HPV negative cancer cells. In 25 addition, N/Tert-1 cells (foreskin keratinocytes immortalized with hTERT) containing 26 HPV16 have elevated levels of ERα and growth sensitivity following estrogen treatment 27 when compared with parental N/Tert-1. Finally, we demonstrate that there are 28 potentially two mechanisms contributing to the attenuation of HPV+ cell growth following 29 estrogen treatment. First, estrogen represses the viral transcriptional long control region 30 (LCR) downregulating early gene expression, including E6/E7. Second, expression of 31 E6 and E7 by themselves sensitizes cells to estrogen. Overall our results support the 32 recent proposal that estrogen could be exploited therapeutically for the treatment of 33 HPV positive oral cancers.34 3 Importance 35Human papillomaviruses cause around 5% of all human cancers, yet there are no 36 specific anti-viral therapeutic approaches available for combating these cancers. These 37 cancers are currently treated with standard chemo-radiation therapy (CRT). Specific 38 anti-viral reagents are desperately required, particularly for HPV+HNSCC whose 39 incidence is increasing and for which there are no diagnostic tools available for 40 combating this disease. Using data from The Cancer Genome Atlas (TCGA) ourselves 41 and others determined that the estrogen receptor α (ERα) is overexpressed in 42 HPV+HNSCC, and that elevated levels are associated with an improved disease 43 outcome. This has led to the proposal that estrogen treatment could be a novel 44 therapeutic approach for combating HPV+cancers. Here we demonstrate that estrogen 45 attenuates the growth of HPV+epithelial cells using multiple mechanisms, supporting 46 the idea that estrogen has potential as a therapeutic agent for the treatment of 47 65 correlates with increased survival in HPV+HNSCC(20, 21). These reports suggest ERα 66 as a diagnostic marker but also raise the possibility of using estrogen as a therapeutic 67 for the treatment of HPV+HNSCC. In...

show abstract

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy

Cited by 171 publications

References 430 publications

Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1

Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1

Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae

Estrogen attenuates the growth of human papillomavirus positive epithelial cells

Contact Info

Product

Resources

About